<DOC>
	<DOCNO>NCT00933335</DOCNO>
	<brief_summary>This single-arm , single institution , phase II study fludarabine monophosphate follow Iodine I 131 Tositumomab patient previously untreated , advanced-stage ( stage III IV ) low-grade , transform low-grade follicular non-Hodgkin 's lymphoma . The primary objective study evaluate safety treatment combination secondary endpoint evaluate efficacy .</brief_summary>
	<brief_title>Study Safety Efficacy Sequential Regimen Consisting Three Cycles Fludarabine Followed Tositumomab Iodine I 131 Tositumomab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Patients must age 18 year old . Patients must histologicallyconfirmed diagnosis lowgrade follicular nonHodgkin 's Bcell lymphoma . Patients must Ann Arbor stage III IV extent disease complete stag . Patients must bidimensionally measurable disease . At least one lesion must perpendicular diameter &gt; 2 cm . Patients must evidence tumor express CD20 antigen immunohistochemistry flow cytometry . Patients must previous treatment NHL . Patients must Karnofsky performance status least 60 % anticipated survival least 3 month . Patients must absolute granulocyte count great equal 1500 cells/mm3 platelet count &gt; 100,000 cells/mm3 within 14 day study entry require sustain support hematopoietic cytokine transfusion blood product . Patients must adequate renal hepatic function . Patients must sign IRB approve informed consent form ( ) prior study entry . Patients receive systemic steroid within 1 week study entry , except patient maintenance steroid therapy noncancerous disease . Patients evidence active infection require intravenous antibiotic time study entry . Patients New York Heart Association class III IV heart disease serious illness would preclude evaluation . Patients know HIV Infection . Patients know brain leptomeningeal metastasis . Patients pregnant nursing . Patients childbearing potential must undergo pregnancy test screen day fludarabine treatment start . Treatment administer negative result obtain . Males female must agree use effective contraception 6 month follow iodine I 131 tositumomab therapy . Patients prior malignancy lymphoma , except adequatelytreated skin cancer situ cervical cancer , cancer patient diseasefree 5 year . Patients hypersensitivity fludarabine . Patients receive either approve nonapproved ( another protocol ) anticancer drug biologics . Patients HAMA positive . Patients previous allergic reaction iodine . This include react intravenous iodine contain contrast material . Inclusion Criteria Iodine I 131 Tositumomab Therapy Patients complete 3 cycle fludarabine . Patients must absolute granulocyte count ≥ 1500/mm3 , platelet count ≥ 100,000/mm3 ( ≥ 150,000/mm3 &gt; 25 % bone marrow involvement restaging ) , require sustained support hematopoietic cytokine transfusion blood product . Patients must adequate renal hepatic function . Exclusion criterion Antibody Therapy Patients active obstructive hydronephrosis . Patients evidence active infection require intravenous antibiotic . Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>